Some researches revealed the presence of squamous cell carcinoma (SCC), wild-type EGFR or KRAS gene mutations was associated with high expression of PD–L1, providing potentially benefits for the administration of PD-1/PD–L1 blockade in lung cancer21. This evidence concerns the gene KRAS and squamous cell carcinoma.